VANCOUVER, Jan. 9 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic tests, announced today that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris(R)).
"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis. This new collaboration with the UKCCG group will allow Sirius Genomics to significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled. We are delighted to be working with the UKCCG group to further our progress towards the commercialization of our first product," commented Dr. Brad Popovich, President and CEO of Sirius Genomics.
"The collaboration with Sirius Genomics is in direct alignment with our objective to disseminate and promote understanding of functional genomics in the wider intensive care community," stated Professor Charles Hinds, one of the Principal Investigators of the UKCCG Group. "We are very excited to be working with Sirius Genomics on this new collaboration."
Financial terms of the agreement were not disclosed.
About UKCCG: www.ukccg-gains.org/index.htm
The UKCCG Group is a collaborative consortium composed of multiple investigators, collaborators and members throughout the United Kingdom representing more than 35 hospitals. The group's primary objective is to undertake clinical functional genomics research in the critically ill and to develop related collaborative, laboratory based research projects with scientific colleagues.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that excels at developing pharmacogenomic (PGx) tests that lead to better patient outcomes through personalized medicine. Sirius' business focus is on generating value through improving the safety and effectiveness of pharmaceutical compounds. The Company's expert medical and business team correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
SOURCE Sirius Genomics Inc.